PanOptica to Present Positive Topical Anti-VEGF Eye Drop Data at OIS@AAO
PAN-90806 is a once-daily topical formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases, including neovascular age-related macular degeneration (wet AMD).
- PAN-90806 is a once-daily topical formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases, including neovascular age-related macular degeneration (wet AMD).
- In pre-clinical research using validated ocular angiogenesis models, topically administered PAN-90806 in the form of an eye drop suppressed the formation of new blood vessels.
- In non-clinical pharmacokinetic studies, topical administration of PAN-90806 achieved significant and sustained levels in the retina and choroid of multiple species, supporting further investigation of PAN-90806.
- The company seeks early-stage assets translated from other diseases and develops select candidates through human clinical proof of concept.